Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trader Talk

Gilead Sciences (GILD) PT Lowered to $87 at Cantor FitzgeraldFebruary 12, 2019 7:14 AM Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84February 12, 2019 6:53 AM Gilead Sciences (GILD) Falls 4% After-Hours Following Failure of Cirrhosis StudyFebruary 11, 2019 4:33 PM Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)February 11, 2019 4:30 PM